Exhibit 99.1
PDMR Dealing
August 21, 2017, LONDON — Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 122.5 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company’s issued share capital.
The notification of dealing form can be found below.
For further information, please contact:
Verona Pharma plc | | Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer | | info@veronapharma.com |
| | |
N+1 Singer (Nominated Adviser and UK Broker) | | Tel: +44 (0)20 7496 3000 |
Aubrey Powell / James White | | |
| | |
FTI Consulting (UK Media and Investor enquiries) | | Tel: +44 (0)20 3727 1000 |
Simon Conway / Natalie Garland-Collins | | veronapharma@fticonsulting.com |
| | |
ICR, Inc. (US Media and Investor enquiries) | | |
Darcie Robinson | | Tel: +1 203-682-8379
Darcie.Robinson@icrinc.com |
Stephanie Carrington | | Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com |
1 | | Details of the person discharging managerial responsibilities/person closely associated |
| | |
a) | | Name | | David Ebsworth |
| | | | |
2 | | Reason for the notification |
| | |
a) | | Position/status | | Non-Executive Chairman |
| | | | |
b) | | Initial notification/Amendment | | Initial notification |
3 | | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| | |
a) | | Name | | Verona Pharma plc |
| | | | |
b) | | LEI | | 213800EVI6O6J3TIAL06 |
| | | | |
4 | | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
| | |
a) | | Description of the financial instrument, type of instrument
Identification code | | Ordinary Shares of 5 pence each
GB00BYW2KH80
|
| | | | |
b) | | Nature of the transaction | | David Ebsworth purchased 8,130 Ordinary Shares |
| | | | |
c) | | Price(s) and volume(s) | | Price(s) | | Volume(s) |
| | | | 122.5 pence per Ordinary Share | | 8,130 Ordinary Shares |
| | | | | | |
d) | | Aggregated information | | N/A |
| | | | |
| | · Aggregated volume | | |
| | | | |
| | · Price | | |
| | | | |
e) | | Date of the transaction | | 17 August 2017 |
| | | | |
f) | | Place of the transaction | | London Stock Exchange, AIM |
